Sage Therapeutics
About Sage Therapeutics
406articles about Sage Therapeutics
-
Sage Therapeutics to Participate in Upcoming May2024 Investor Conferences 5/7/2024 Sage Therapeutics，Inc.，abiopharmaceutical company leading the way to create a world with better brain health，announced that the Company will participate in the following upcoming investor conferences in May:2024RBCCM Global Healthcare Conference:fireside chat on Tuesday，May14230at:30.ETm。 -
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress 4/25/2024 Sage Therapeutics，Inc.，abiopharmaceutical company leading the way to create a world with better brain health，reported business high lights and financial results for the first quarter ended March312024。 -
Sage Therapeutics Announces Topline Results from Phase2PRECEDENT Study of Dalzanemdor（SAGE-718）in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease 4/17/2024 Sage Therapeutics，Inc.announced topline results from PRECEDENT，a double-blind，placebo-controlled Phase2study of the investigational oral medicine dalzanemdor in people with mild cognitive impairment in Parkinson’s Disease。 -
Sage Therapeutics announced Wednesday it is scrapping its Parkinson’s disease program after the company’s investigational drug showed no benefit over placebo。 Phase II studies of the oral treatment will continue in Huntington’s and Alzheimer’s diseases。 -
Sage Therapeutics to Report First Quarter2024 Financial Results on Thursday，April252024 4/11/2024 Sage Therapeutics，Inc.，abiopharmaceutical company leading the way to create a world with better brain health，announced that it will host a live webcast on Thursday，April252024at8:00a.m.ET to review first quart2024financial results and discuss recent business updates。 -
Looking fora biopharma job？ Check out the BioSpace list of 11 top companies hiring life sciences professionals like you。 -
Sage Therapeutics to Present at Upcoming March Investor Conferences 2/28/2024 Sage Therapeutics，Inc.announced today that the Company will present at the following upcoming investor conferences in March。 -
后支路深度驱动装置 2/15/2024 Despite missing out on an FDA approval for major depressive disorder，Zurzuvae appears to be astrong asset for Sage Therapeutics，with high growth potential in 2024。 -
Sage Therapeutics Announces Fourth Quarter and Full Year2023 Financial Results and Highlights Pipeline and Business Progress 2/14/2024 Sage Therapeutics，Inc.（Nasdaq:SAGE），a biopharmaceutical company leading the way to create a world with better brain health，today reported business highlights and financial results for the fourth quarth and full year ended December312023。 -
Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday，February 142024 1/31/2024 Sage Therapeutics，Inc.（NASDAQ:SAGE），a biopharmaceutical company leading the way to create a world with better brain health，today announced that it will host a live webcast on Wednesday，February142024at8:00a.m.ET to review fourth quarth and full year2023financial results and scusdiessdates。 -
Sage Therapeutics to Provide Business Updates at42nd Annual J.P.Morgan Healthcare Conference 1/8/2024 Sage Therapeutics，Inc.announced that Chief Executive Officer Barry Greene will discuss the Company’s key business drivers for 2024at the 42nd Annual J.P.Morgan Healthcare Conference in San Francisco，California。 -
Sage Therapeutics Announces Changes to Board of Directors-Jan082024 1/8/2024 Sage Therapeutics，Inc.，abiopharmaceutical company leading the way to create a world with better brain health，announced the retirement of Kevin Starr from the company’s board of directors。 -
With recent scientific advances，milestone approvals and increased dealmaking，the future of treatment forneurological diseases looks brighter—but continued investment，collaboration and patient-focued efforts are key。 -
Sage Therapeutics to Present at the 42nd Annual J.P.Morgan Healthcare Conference on Monday，January82024 1/2/2024 Sage Therapeutics，Inc.announced today that the Company will present at the 42nd Annual J.P.Morgan Healthcare Conference on Monday，January82024at4:30p.m.PT in San Francisco，CA。 -
ZURZUVAE ™，™ （zuranolone）CIV，a Landmark Oral Treatment for Women with Postpartum Depression（PPD），is Now Available in the U.S。 12/14/2023 Biogen Inc.and Sage Therapeutics，Inc.announced ZURZUVAE ™，™ 50mg CIV is now available by prescription for the treatment of postpartum depression for adults in the United States，with product already at specialty pharmacies and delivered to patients。 -
Sage Therapeutics to Present at Upcoming November 2023 Investor Conferences 11/8/2023 Sage Therapeutics，Inc.announced that the Company will present at the following upcoming investor conferences in November。 -
Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress 11/7/2023 Sage Therapeutics，Inc.reported business high lights and financial results for the third quarter ended September 302023。 -
Sage Therapeutics to Report Third Quarter2023 Financial Results on Tuesday，November72023 10/24/2023 Sage Therapeutics，Inc.announced that it will host a live webcast on Tuesday，November72023at8:00a.m.ET to review third quarter2023financial results and discuss recent business updates。 -
Sage Therapeutics Announces U.S.Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease 10/18/2023 Sage Therapeutics，Inc.，abiopharmaceutical company leading the way to create a world with better brain health，announced the U.S.Food and Drug Administration granted Orphan Drug Designation to SAGE-718 for the treatment of Huntington’s disease。 -
Week in Review:Amgen-Horizon Deal Moves Forward，First10 Drugs for IRA Price Negotiation，Layof。。。 9/1/2023 27.8美元B Amgen-Horizon deal gets FTC clearance with restrictions； the White House name s first10 drugs subject to Medicare price negotiations； Sage Therapeutics axes40%of staff。